Quantcast
Home > Quotes > PRTA
PRTA

Prothena Corporation plc Ordinary Shares (PRTA) Quote & Summary Data

$15.67
*  
0.63
4.19%
Get PRTA Alerts
*Delayed - data as of Jun. 22, 2018  -  Find a broker to begin trading PRTA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
14
Today's High / Low
$ 15.68 / $ 14.83
Share Volume
1,880,429
50 Day Avg. Daily Volume
1,224,923
Previous Close
$ 15.04
52 Week High / Low
$ 70 / $ 10.43
Market Cap
624,016,005
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.33
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.67

Intraday Chart

Shares Traded

Share Volume:
1,880,429
50 Day Avg. Daily Volume:
1,224,923

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.33

Trading Range

The current last sale of $15.67 is 50.24% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.68 $ 70
 Low: $ 14.83 $ 10.43

Company Description (as filed with the SEC)

Prothena Corporation plc ("Prothena" or the "Company") is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan disease categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company continues to advance additional discovery programs where our deep scientific understanding of disease pathology can be leveraged.  ... More ...  

Risk Grade

Where does PRTA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 15.12
Open Date:
Jun. 22, 2018
Close Price:
$ 15.67
Close Date:
Jun. 22, 2018

Consensus Recommendation

Analyst Info